The TGA has published a web page outlining new priority areas for compliance activities relating to the import, advertising and supply requirements of the Therapeutic Goods Act 1989 from 1 July 2022 to 30 June 2023, and includes matters relating to unapproved goods, e-commerce supply of unapproved goods; COVID-19 or serious diseases; sports supplements; and medicinal cannabis.

In particular CMA has supported TGA deterring and addressing the unlawful advertising of unapproved therapeutic goods (goods not listed on ARTG when required) on e-commerce platforms to Australian consumers. CMA supports monitoring and deterring the supply of illegal and unauthorised therapeutic goods in Australia, including via representation on the Therapeutic Goods Advertising Consultative Committee (TGACC), which identified that the supply of unapproved therapeutic goods that advertised non-compliantly on e-commerce platforms presents a risk to Australian consumers and industry.

This technical alert provides a summary of these TGA compliance priorities and includes additional information and resources where applicable or relevant, for member consideration.